
BIOVENTUS INC - A
BVSNASDAQTrading Snapshot
- Day Range
- $13.53 β $13.92
- 52-Week Range
- $6.26 β $15.89
- Volume
- $2.81B
- Avg Volume
- $1.90B
- Shares Outstanding
- 67.8M
- Next Earnings
- Sep 11, 2026
Fundamentals Snapshot
- Annual Revenue
- $568M
- Last Q Revenue
- $153M
- P/E Ratio
- 41.2
- P/S Ratio
- 2.0x
- EPS (TTM)
- $0.41
- Dividend Yield
- β
Why Investors Own BVS
- βHigh-growth profile β revenue up +17.7% YoY with expanding US Equity exposure.
- βHealthy economics β 51% gross margin and 26% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About BIOVENTUS INC - A
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The companyβs product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The companyβs restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.
Otter Score Breakdown
βAnalyst Ratings
βLatest News & Updates

Deal Dispatch: Bending Spoons Acquires Airtable, Bain Capital Buys Gong Cha Global, Salad and Go Bankruptcy
Major M&A deals include Visa buys BioCatch, Apollo Global nabs EasyJet, QVC emerges from Chapter 11 bankruptcy.

Bioventus Inc. 2026 Q2 - Results - Earnings Call Presentation
2026-08-05. The following slide deck was published by Bioventus Inc.

Bioventus Inc. (BVS) Q2 2026 Earnings Call Transcript
Bioventus Inc. (BVS) Q2 2026 Earnings Call August 5, 2026 8:30 AM EDTCompany ParticipantsDavid Crawford - Vice President of Investor Relations &...
Bioventus (NASDAQ:BVS) Falls After Q2 Revenue Miss, Launches Strategic Review
Bioventus shares drop ~7% premarket on Q2 revenue miss, though EPS meets estimates; company launches strategic review.
Bioventus Q2 Adj. EPS $0.22, Inline, Sales $153.208M Miss $155.640M Estimate
Bioventus (NASDAQ:BVS) reported quarterly earnings of $0.22 per share which met the analyst consensus estimate. This is a 4.76 percent increase over earnings of $0.21 per share from the same period last year. The
Bioventus Affirms FY2026 Adj EPS Guidance of $0.75-$0.79 vs $0.78 Est; Affirms FY2026 Sales Guidance of $600.000M-$610.000M vs $605.756M Est
Bioventus (NASDAQ:BVS) affirms FY2026 Adj EPS guidance from $0.75-$0.79 to $0.75-$0.79 vs $0.78 analyst estimate. Affirms FY2026 sales outlook from $600.000 million-$610.000 million to $600.000 million-$610.000 million